v3.26.1
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2022
Significant Accounting Policies [Line Items]            
Issuance of fair value     $ 29,259   $ 6,242  
Recognized income     975      
Deferred income $ 1,209   1,209   $ 1,269  
Straight-line income recognition     454      
Gain from sale of IP     5,821    
Non refundable consideration           $ 2,000
Other income 610 $ 257 8,860 $ 257    
Excess Cost     6,500      
Variable interest entity [Member]            
Significant Accounting Policies [Line Items]            
Interest $ 28,823   $ 28,823      
Alpha Tau [Member]            
Significant Accounting Policies [Line Items]            
Purchase warrant (in Shares) 3,237,000   3,237,000      
Issuance of fair value     $ 2,727      
Non cash income     500      
Total non cash income     3,000      
Recognized income     500      
Deferred income $ 313   313      
Clinical Trial Management Agreement with Oratech Ltd. [Member]            
Significant Accounting Policies [Line Items]            
Recognized income 93   93      
Deferred income 882   882      
Oratech Ltd. [Member]            
Significant Accounting Policies [Line Items]            
Cash 6,500   6,500      
Excess Cost     6,500      
Services and expenses $ 622          
Medicox License Agreement [Member]            
Significant Accounting Policies [Line Items]            
Other income     $ 2,000      
Minimum [Member] | Alpha Tau [Member]            
Significant Accounting Policies [Line Items]            
Ownership percentage 20.00%   20.00%      
Maximum [Member] | Alpha Tau [Member]            
Significant Accounting Policies [Line Items]            
Ownership percentage 50.00%   50.00%